The current stock price of AKYA is 1.29 USD. In the past month the price increased by 13.16%. In the past year, price decreased by -44.16%.
ChartMill assigns a technical rating of 4 / 10 to AKYA. When comparing the yearly performance of all stocks, AKYA is a bad performer in the overall market: 90.51% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to AKYA. Both the profitability and financial health of AKYA have multiple concerns.
Over the last trailing twelve months AKYA reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 31.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
11 analysts have analysed AKYA and the average price target is 1.45 USD. This implies a price increase of 12.08% is expected in the next year compared to the current price of 1.29.
For the next year, analysts expect an EPS growth of 38.62% and a revenue growth 4.99% for AKYA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
AKOYA BIOSCIENCES INC
100 Campus Drive, 6th Floor
Marlborough MASSACHUSETTS US
CEO: Brian McKelligon
Employees: 330
Phone: 18558968401
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
The current stock price of AKYA is 1.29 USD. The price decreased by -5.15% in the last trading session.
AKYA does not pay a dividend.
AKYA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
AKYA stock is listed on the Nasdaq exchange.
You can find the ownership structure of AKOYA BIOSCIENCES INC (AKYA) on the Ownership tab.